Drug Trial Radar · NCT06321068
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Apr 9, 2024
Primary completion
May 30, 2025
Study completion Aug 7, 2025
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy;Phase III study: Confirmatory safety and efficacy study of BAT1308 combined with platinum-containing chemotherapy for first-line treatment of advanced or recurrent mismatch repair protein-deficient (dMMR) endometrial carcinoma
Conditions
- Endometrial Cancer
Interventions
carboplatinDrug
the usage and dosage should be determined by the investigator
PaclitaxelDrug
the usage and dosage should be determined by the investigator
Recombinant humanized anti-PD-1 monoclonal antibody injectionDrug
Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- vital signsTime frame: Through study completion, 1 year
- Physical examinationTime frame: Through study completion, 1 year
- Adverse eventsTime frame: From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy, whichever occurs earlier,assessed up to 1 year
- Clinical laboratory testsTime frame: Through study completion, 1 year
- Clinical auxiliary testsTime frame: Through study completion, 1 year
- Dose-limiting toxicity (DLT)Time frame: From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy,assessed up to 1 year
- Progression Free SurvivalTime frame: Tumor imaging assessments will be performed once every 6 (±7) days during the screening period, once every 6 (±7) days after initial dosing to 25 weeks, and once every 9 (±7) weeks,assessed up to 1 year,the screening period is 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.